Prof Merlin Thomas - Healthed

Experts / Prof Merlin Thomas

Prof Merlin Thomas

Clinician Scientist; Program Leader, Department of Diabetes, Monash University

Professor Merlin Thomas is a clinician scientist and program leader in the Department of Diabetes at Monash University. He is also a Fellow of the Australian Academy of Medicine Science and Founder of RAGE Biotech. His research program is focused on understanding the mechanisms of diabetic complications and developing new opportunities for their prevention and treatment.

More from this expert

Diabetes and metabolism, Renal medicine

Podcasts

SGLT2s and renal protection

Understand CKD screening priorities, risk mitigation strategies, and the role of SGLT-2 inhibitors in preventing progression and complications.

Diabetes and metabolism

Podcasts

T2D and the foot

The aim of the game in managing patients with T2DM is to keep them out of hospital; diabetic foot complications are a common and recurrent reason for patients to be admitted to hospitals

Diabetes and metabolism

Podcasts

T2D and the kidney

CKD is a marker of poor prognosis and if present, we must work hard to prevent adverse outcomes… now is the time for SGLT2i, statins, ace inhibitors, and arbs

Diabetes and metabolism

Monographs

SGLT2 and DPP4 Inhibition: An Ideal Combination

This article discusses the evidence for the combination use of SGLT2 inhibitors and DPP4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

Diabetes and metabolism

Monographs

DPP-4 Inhibitors: Similarities and Differences

This article discusses the evidence for the use of DPP-4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

Diabetes and metabolism

Monographs

DPP-4 Inhibition: Playing the Long Game in Type 2 Diabetes

This article discusses the evidence for the use of DPP-4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

Diabetes and metabolism

Monographs

Combining SGLT2 and DPP-4 Inhibition in Type 2 Diabetes

This article discusses the evidence for using a combination of SGLT2 inhibitors & DPP-4 inhibitors in addition to standard care for the management of type 2 diabetes and its complications.

Diabetes and metabolism

Monographs

Diabetes in the Older Adult

This article discusses the complications and considerations associated with managing older patients with type 2 diabetes and the need for an individualised approach.

Diabetes and metabolism

Monographs

Controlling Glucose in Patients with Renal Impairment

This article discusses common co-morbidities of type 2 diabetes and poor kidney function, and how optimal management must account for the mutual effects of one condition on the other.

Diabetes and metabolism

Monographs

Managing Diabetes in Patients with Liver Disease

This article discusses how to assess abnormal liver function in a patient with type 2 diabetes, and the importance of managing this condition to improve long-term health outcomes.

Controlling Glucose in Patients with Renal Impairment

This article discusses common co-morbidities of type 2 diabetes and poor kidney function, and how optimal management must account for the mutual effects of one condition on the other.

By Prof Merlin Thomas

Monographs

Diabetes and metabolism

Managing Diabetes in Patients with Liver Disease

This article discusses how to assess abnormal liver function in a patient with type 2 diabetes, and the importance of managing this condition to improve long-term health outcomes.

By Prof Merlin Thomas

Monographs

Diabetes and metabolism

Diabetes in the Older Adult

This article discusses the complications and considerations associated with managing older patients with type 2 diabetes and the need for an individualised approach.

By Prof Merlin Thomas

Monographs

Diabetes and metabolism

Combining SGLT2 and DPP-4 Inhibition in Type 2 Diabetes

This article discusses the evidence for using a combination of SGLT2 inhibitors & DPP-4 inhibitors in addition to standard care for the management of type 2 diabetes and its complications.

By Prof Merlin Thomas

Monographs

Diabetes and metabolism

DPP-4 Inhibition: Playing the Long Game in Type 2 Diabetes

This article discusses the evidence for the use of DPP-4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

By Prof Merlin Thomas

Monographs

Diabetes and metabolism

DPP-4 Inhibitors: Similarities and Differences

This article discusses the evidence for the use of DPP-4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

By Prof Merlin Thomas

Monographs

Diabetes and metabolism

SGLT2 and DPP4 Inhibition: An Ideal Combination

This article discusses the evidence for the combination use of SGLT2 inhibitors and DPP4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

By Prof Merlin Thomas

Monographs

Diabetes and metabolism

T2D and the kidney

CKD is a marker of poor prognosis and if present, we must work hard to prevent adverse outcomes… now is the time for SGLT2i, statins, ace inhibitors, and arbs

By Prof Merlin Thomas

Podcasts

Diabetes and metabolism

T2D and the foot

The aim of the game in managing patients with T2DM is to keep them out of hospital; diabetic foot complications are a common and recurrent reason for patients to be admitted to hospitals

By Prof Merlin Thomas

Podcasts

Diabetes and metabolism

SGLT2s and renal protection

Understand CKD screening priorities, risk mitigation strategies, and the role of SGLT-2 inhibitors in preventing progression and complications.

By Prof Merlin Thomas

Podcasts

Diabetes and metabolism, Renal medicine